Early BCR-ABL Predicts Survival in Nilotinib-Treated CML
July 12, 2012|Oncology Practice
Author and Disclosure Information
AT THE ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
"The 3-year update shows a continuation of messages that we saw earlier in the study," Dr. Clark said. There were "significantly higher rates of all molecular responses, there’s no evidence that there is any difference according to Sokal risk in terms of outcome, and there are fewer progressions [to advanced-phase disease] on nilotinib."
The ENESTnd trial was funded by Novartis. The DASISION trial was funded by Bristol-Myers Squibb. Dr. Hochhaus and Dr. Clark had ties with Novartis, BMS, and other companies.
